Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04452292 · ClinicalTrials.gov registry record · NA
Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma
A NA study of Large Cell Neuroendocrine Carcinoma, sponsored by Charles Kunos.
- Completed
- Registry status
- NA
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT04452292 is a NA study of Large Cell Neuroendocrine Carcinoma that has completed, run by Charles Kunos. The registered enrollment target is 2 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04452292, a NA study of Large Cell Neuroendocrine Carcinoma, has completed, sponsored by Charles Kunos.
- COMPLETED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
PRECISION-NEC is a single-center, open-label, pilot feasibility study of molecularly defined subtypes of metastatic high-grade neuroendocrine carcinoma (HG-NEC). The hypothesis is that HG-NEC (excluding small cell carcinoma) can be segregated based on mutational analysis and that next generation sequencing (NGS)-based assignment of therapy is feasible and will potentially improve the outcomes.
Conditions Studied
Interventions
- OTHER Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma
- OTHER Treatment for Small Cell Lung Cancer
Study Locations (1)
Kentucky
- Markey Cancer Center, University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-09-14 |
| Est. Completion | 2023-03-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04452292
The ClinicalTrials.gov registry entry for NCT04452292 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Charles Kunos, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Large Cell Neuroendocrine Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma is the first listed.
NCT04452292 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT04452292 about?
NCT04452292 is a clinical study titled "Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma". PRECISION-NEC is a single-center, open-label, pilot feasibility study of molecularly defined subtypes of metastatic high-grade neuroendocrine carcinoma (HG-NEC). The hypothesis is that HG-NEC (excluding small cell carcinoma) can be segregated based on mutational analysis and that next generation seq...
What is the current status of trial NCT04452292?
This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2021-09-14. Estimated completion is 2023-03-14.
What conditions does trial NCT04452292 study?
This clinical trial studies the following conditions: Large Cell Neuroendocrine Carcinoma.
What interventions are being tested in trial NCT04452292?
The interventions under investigation include: Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma (OTHER), Treatment for Small Cell Lung Cancer (OTHER).
Who is sponsoring clinical trial NCT04452292?
This trial is sponsored by Charles Kunos, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04452292 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large Cell Neuroendocrine Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
RECRUITING · Phase 1
-
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.